Endoscopic survey of low-dose-aspirin-induced gastroduodenal mucosal injuries in patients with ischemic heart disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue SUPPL. 2, 2008, Pages

  Nema, Hiroaki ^a   Kato, Mototsugu ^b   Katsurada, Takehiko ^b   Nozaki, Youichi ^a   Yotsukura, Akihiko ^a   Yoshida, Izumi ^a   Sato, Katsuhiko ^a   Kawai, Yuko ^a   Takagi, Yasushi ^a   Okusa, Takanori ^a   Takiguchi, Shunichi ^c   Sakurai, Masayuki ^a   Asaka, Masahiro ^c  

^a Hokko Memorial Hospital   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Buffered formulation; Enteric coated formulation; Ischemic heart disease; Low dose aspirin; Mucosal defects

Indexed keywords

ACETYLSALICYLIC ACID; BAYASPIRIN; UNCLASSIFIED DRUG;

ADULT; AGED; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DUODENUM INJURY; DUODENUM ULCER; ENDOSCOPY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; STOMACH ULCER; TREATMENT DURATION;

EID: 57449084900     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05411.x     Document Type: Conference Paper

References (12)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of ant platelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 324 : 71 86.
2. Lauer MS. Aspirin for primary prevention of coronary events. N. Engl. J. Med. 2002 346 : 1468 74.
3. Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosal legions. Aliment. Pharmacol. Ther. 1999 13 : 1109 14.
4. Hawthorne AB, Mahida YR, Cole AT, Howkey CJ. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br. J. Clin. Pharmacol. 1991 32 : 77 83.
5. Cole AT, Hudson N, Hawkey CJ, Hepinstall S. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction? Aliment. Pharmacol. Ther. 1999 13 : 187 93.
6. Muramatsu A, Azuma T, Okajima T et al. Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan. Aliment. Pharmacol. Ther. 2004 20 (Suppl. 1 102 6.
7. Bochner F, Siebert DM, Rodgers SE, McIntosh GH, James MJ, Lloyd JV. Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production. Thromb. Haemost. 1989 61 : 211 16.
8. Awtry EH, Loscalzo J. Aspirin. Circulation 2000 101 : 1206 18.
9. Benedek IH, Joshi AS, Pieniaszek HJ, King SY, Kornhauser DM. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J. Clin. Pharmacol. 1995 35 : 1181 6.
10. Gartner AH. Aspirin-induced gastritis and gastrointestinal bleeding. J. Am. Dent. Assoc. 1976 93 : 111 17.
11. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996 348 : 1413 16.
12. Rodriguez LAG, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994 343 : 769 72.